A 55-year-old man is in the intensive care unit being managed for recurrent seizures secon… — USMLE Step 3

A 55-year-old man is in the intensive care unit being managed for recurrent seizures secondary to viral encephalitis. His seizures have been well-controlled for the past week on a continuous intravenous infusion of valproic acid. On hospital day 8, he developed a new fever, increased respiratory secretions, and a right lower lobe consolidation on chest radiograph. Sputum and blood cultures were obtained, and he was started empirically on intravenous meropenem. On hospital day 10, the patient experiences a 3-minute generalized tonic-clonic seizure.

Relevant laboratory results are shown below:

Parameter	Hospital Day 7	Hospital Day 9	Hospital Day 10 (Today)	Reference Range
Leukocyte count	$8,500/\mu L$	$15,200/\mu L$	$14,800/\mu L$	$4,000-11,000/\mu L$
Serum valproic acid	$85\ \mu g/mL$	$35\ \mu g/mL$	$12\ \mu g/mL$	$50-100\ \mu g/mL$
Serum creatinine	$0.9\ mg/dL$	$0.9\ mg/dL$	$1.0\ mg/dL$	$0.6-1.2\ mg/dL$

Which of the following is the most appropriate next step in the management of this patient?

A
Increase the infusion rate of valproic acid
B
Check prothrombin time and activated partial thromboplastin time
Discontinue meropenem and initiate an alternative antipseudomonal antibioticCevap
D
Obtain an electroencephalogram before adjusting medications
E
Add intravenous imipenem-cilastatin to broaden antimicrobial coverage

Cevap

The correct action is to discontinue meropenem and initiate an alternative antipseudomonal antibiotic.

The correct management is to discontinue the interacting antibiotic. Meropenem, like all carbapenems, is well known to cause a precipitous and profound decrease in serum valproic acid concentrations, frequently leading to subtherapeutic levels and breakthrough seizures within 24 to 48 hours of initiation. Because this interaction is rapid and difficult to overcome with dose adjustments, the standard of care is to substitute the carbapenem with a different class of antibiotics, such as a cephalosporin or a penicillin derivative.

Adım Adım Çözüm

Analyze the clinical timeline and presentation.

A patient with previously controlled seizures develops breakthrough generalized tonic-clonic seizures two days after starting a new medication (meropenem).

Establishing the timeline is critical for identifying potential drug-drug interactions or adverse events.

Evaluate the longitudinal laboratory data.

The serum valproic acid level dropped precipitously from a therapeutic level of

85\ \mu g/mL

to a subtherapeutic level of

12\ \mu g/mL

concurrently with the administration of meropenem.

Serial labs confirm that the loss of seizure control is directly due to subtherapeutic antiepileptic drug levels rather than structural neurological worsening.

Identify the underlying pharmacokinetic mechanism.

Carbapenem antibiotics (e.g., meropenem, imipenem, ertapenem) rapidly and profoundly decrease serum valproic acid concentrations.

This occurs via inhibition of intestinal absorption, increased erythrocyte distribution, and enhanced hepatic clearance (glucuronidation).

Determine the appropriate treatment adaptation.

The offending agent (meropenem) must be discontinued and substituted with an alternative antibiotic (e.g., cefepime or piperacillin-tazobactam) to allow valproic acid levels to recover.

Simply increasing the valproic acid dose cannot reliably overcome this severe interaction.

Anahtar Kavram

Carbapenem antibiotics cause a rapid and clinically significant decrease in serum valproic acid levels, often leading to breakthrough seizures; the appropriate management is to discontinue the carbapenem.

Soru

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Konular

Bu konudan daha fazla soru